According to a recent LinkedIn post from DeepScribe, newly published research in JAMA Network Open is described as reinforcing evidence of significant testing gaps in precision oncology. The post notes that among more than 63,000 patients with five types of advanced or metastatic cancer, the majority reportedly did not receive tumor genomic testing despite the availability of life‑prolonging targeted therapies.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The LinkedIn post highlights that the abstract of the study cites disparities in next‑generation sequencing access along racial and financial lines. It also references prior commentary by Matthew Ko on coordination failures in precision oncology, including patients not receiving appropriate targeted therapies and guideline recommendations being overlooked by overburdened oncologists.
As interpreted in the post, these systemic gaps may create a growing need for tools that better coordinate personalized cancer care, particularly as treatment pathways become more complex. The discussion suggests that AI‑driven solutions could help relieve clinician workload, ensure adherence to testing guidelines, and improve matching of patients to targeted therapies, potentially expanding the addressable market for technology vendors in oncology workflows.
For investors, the focus on AI’s role in closing testing and coordination gaps points to an emerging health‑IT opportunity tied to precision medicine adoption. If companies such as DeepScribe can demonstrate that their technology enhances care coordination, reduces missed testing, and supports guideline‑concordant treatment decisions, they could strengthen their value proposition to health systems and payers and benefit from long‑term oncology digitization trends.